Gilead Sciences (GILD) Equity Average (2009 - 2026)

Gilead Sciences has reported Equity Average for 18 years, with the latest figure at $23.1 billion in Q1 2026.

• For the quarter ending Q1 2026, Equity Average rose 20.6% year-over-year to $23.1 billion; the trailing twelve-month figure through Mar 2026 stood at $23.1 billion (up 20.6% YoY), and the FY2025 full-year result was $21.0 billion, changed 0.11% from the prior year.
• Equity Average for Q1 2026 stood at $23.1 billion, up from $22.1 billion in the prior quarter.
• The five-year high for Equity Average was $23.1 billion in Q1 2026, with the low at $17.8 billion in Q2 2024.
• Historically, Equity Average has averaged $20.5 billion across 5 years, with a median of $20.6 billion in 2025.
• Annual changes were most pronounced in 2024 — Equity Average declined 16.35% — and 2026, when it gained 20.6%.
• Gilead Sciences' Equity Average stood at $21.1 billion in 2022, then rose by 6.45% to $22.5 billion in 2023, then fell by 16.35% to $18.8 billion in 2024, then grew by 17.56% to $22.1 billion in 2025, then gained by 4.46% to $23.1 billion in 2026.
• The last three Equity Average figures came in at $23.1 billion (Q1 2026), $22.1 billion (Q4 2025), and $20.6 billion (Q3 2025), per Business Quant data.